NKGen Biotech, Inc. Warrants
NKGNW
NKGNW was delisted on the 4th of March, 2025.
27 hedge funds and large institutions have $4.43M invested in NKGen Biotech, Inc. Warrants in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
52% more capital invested
Capital invested by funds: $2.92M → $4.43M (+$1.51M)
17% more funds holding
Funds holding: 23 → 27 (+4)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Periscope Capital
Toronto,
Ontario, Canada
|
+$122K |
| 2 |
KC
Kepos Capital
New York
|
+$107K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$20.3K |
| 4 |
CCM
CAAS Capital Management
New York
|
+$10.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIMCA
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
|
-$46K |
| 2 |
EAM
Exos Asset Management
New York
|
-$16K |
| 3 |
EIP
Easterly Investment Partners
Beverly,
Massachusetts
|
-$12K |
| 4 |
Walleye Capital
New York
|
-$293 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
26
Walleye Capital
New York
| $12K | -$293 | -288 | -3% |
|
|
CCM
27
CAAS Capital Management
New York
| $12K | +$10.2K | +10,000 | New |
|
|
FLC
28
Fifth Lane Capital
Austin,
Texas
| $12K | +$10.4K | +10,220 | New |
|
|
AIMCA
29
Alberta Investment Management Corp (AIMCo)
Edmonton,
Alberta, Canada
| – | -$46K | -40,000 | Closed |
|
|
EAM
30
Exos Asset Management
New York
| – | -$16K | -14,000 | Closed |
|
|
EIP
31
Easterly Investment Partners
Beverly,
Massachusetts
| – | -$12K | -10,000 | Closed |
|
NKGNW Hedge Fund Activity: Q4 2021 in Review
27 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in NKGen Biotech, Inc. Warrants (NKGNW) for Q4 2021, worth a combined $4.43M — up 52% from $2.92M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new NKGNW positions and 3 closed out — a net gain of 4 holders — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Periscope Capital, opening a new position worth an estimated $122K. The largest seller was Alberta Investment Management Corp (AIMCo), exiting entirely with an estimated $46K sold.
- 27 institutional investors held NKGen Biotech, Inc. Warrants (NKGNW) as of Q4 2021, up from 23 in Q3 2021.
- Funds reported $4.43M of NKGen Biotech, Inc. Warrants stock for Q4 2021, up 52% quarter-over-quarter.
- 7 funds opened new NKGen Biotech, Inc. Warrants positions in Q4 2021 and 3 closed out, a net change of +4 holders.
- The largest NKGen Biotech, Inc. Warrants buyer in Q4 2021 was Periscope Capital, an estimated $122K added.
- The largest NKGen Biotech, Inc. Warrants seller in Q4 2021 was Alberta Investment Management Corp (AIMCo), an estimated $46K sold.
Based on aggregated 13F filings for Q4 2021.